CERo Therapeutics Holdings, Inc. (CERO)
| Market Cap | 759.21K -86.5% |
| Revenue (ttm) | n/a |
| Net Income | -95.30M |
| EPS | -4.08 |
| Shares Out | 75.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 474,404 |
| Open | 0.0115 |
| Previous Close | 0.0110 |
| Day's Range | 0.009675 - 0.0115 |
| 52-Week Range | 0.0070 - 5.7200 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About CERO
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company’s lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California. [Read more]
Financial Performance
Financial StatementsNews
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic maligna...
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF)
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.,...
Cero Therapeutics issues letter to shareholders
CERo Therapeutics (CERO) provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich: “Following our recent Form 8-K filing confirming receipt of convertible debt fun...
CERo Therapeutics Provides Shareholder Update
Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead inve...
Cero Therapeutics appoints Eric Francois to board of directors
CERo Therapeutics Holdings (CERO) announces the appointment of Eric Francois to the Company’s Board of Directors. Formerly, he served as CFO of SCYNEXIS (SCYX).
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targe...
Cero Therapeutics to present data from Phase 2 trial of CER-1236
CERo Therapeutics (CERO) announces a presentation highlighting data to date from the Company’s Phase 1 clinical trial, called CERTAIN-T, of its lead compound, CER-1236. Reflective of the Company’s rec...
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on Febru...
Cero Therapeutics provides update on Phase 1 trial of CER-1236
CERo Therapeutics (CERO) announces a key clinical update from the Company’s ongoing CertainT-1 trial focused on patients with acute myeloid leukemia. Following completion of the dose-limiting toxicity...
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, In...
Cero Therapeutics provides update on Phase 1 trial of CER-1236
CERo Therapeutics (CERO) announces recent advances to the CertainT-1 trial that is focused on patients with acute myeloid leukemia (AML). Following completion of the dose-limiting toxicity observation...
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1
Cero Therapeutics announces trading on OTCQB Market
CERo Therapeutics (CERO) announces its shares will be available to trade on the OTCQB market under the ticker symbol CERO effective today, December 2, 2025 as of 8:00AM ET. No…
CERo Therapeutics Announces Trading on OTCQB Market
Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”), an i...
Cero Therapeutics downgraded to Hold from Buy at D. Boral Capital
D. Boral Capital analyst Jason Kolbert downgraded Cero Therapeutics (CERO) to Hold from Buy with no price target Q3 preliminary results highlight capital structure headwinds and the company is delayin...
Cero Therapeutics initiates second cohort in Phase 1 trial of CER-1236
CERo Therapeutics (CERO) announces the initiation of the second cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia. The first patient in the cohort…
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new ta...
Cero Therapeutics to present data on CER-1236 at SITC conference
CERo Therapeutics (CERO) will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer conference being held November 5-9, 2025 in National Harbor, Md. The…
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo...
Cero Therapeutics announces listing on OTC Markets
CERo Therapeutics (CERO) announces its shares continue to be listed on the public markets under the ticker symbol CERO. Effective as of market open on Friday, October 31, 2025, the…
Cero Therapeutics downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Cero Therapeutics (CERO) to Hold from Buy.
Cero Therapeutics discloses Nasdaq Panel listing determination
CERo Therapeutics (CERO) “announced the receipt of the determination of the Nasdaq Hearings Panel to deny the Company’s request to continue the listing of its shares of common stock on…
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Mar...